Sativex® is an oromucosal spray of a formulated extract of the cannabis sativa plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:1 ratio (US approved name: nabiximols) as well as specific minor cannabinoids and other non-cannabinoid components. We developed Sativex to be administered as an oromucosal spray, whereby the active ingredients are absorbed in the lining of the mouth, either under the tongue or inside the cheek. We have received regulatory approval for Sativex in 30 countries so far (outside the United States) In Europe, Sativex has now received marketing authorization in 21 countries for the treatment of spasticity (muscle stiffness/spasm) due to MS, which include: Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Iceland, Ireland, Italy, Lichtenstein, Luxembourg, Netherlands, Norway, Poland, Portugal, Slovakia, Spain, Sweden, Switzerland and the United Kingdom. Beyond Europe, Sativex has received full regulatory approval for MS spasticity in Canada, Australia, New Zealand, Brazil, Colombia, Chile, UAE & Kuwait and achieved approval in Israel for the indications of MS Spasticity and pain and for chronic cancer pain.
GW does not market Sativex directly. All requests for product information and adverse events reporting should be directed through the individual websites for the distributors listed in the HCP section.